Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Race Oncology is reformulating bisantrene (RAC-220) to prevent chemotherapy-induced heart damage, with a phase 1 cardioprotection trial planned for early 2025. The trial will enroll 25-40 patients across multiple sites. The company has also reported promising results from a phase 1b/2 trial using the original bisantrene formulation (RC-110) in treating acute myeloid leukemia.
Read the full article via this link